Sunday, September 29, 2024
HomeTagsVersatile platform

versatile platform

Triumvira Immunologics Announces First Patient Dosed in Phase II of TACTIC-2 Cell Therapy Trial for the Treatment of HER2+ Gastric and GEJ Cancers

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics